Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876970 | 0.86 | ALOX15 (0.55) | NPC1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4866180 | 0.85 | NPC1 (0.54) | NPC1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4866163 | 0.85 | NPC1 (0.54) | NPC1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6181864 | 0.82 | MAPT (0.48) | NPC1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5260111 | 0.81 | NPC1 (0.45) | NPC1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL23217923 | 0.80 | NPC1 (0.40) | NPC1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29796592 | 0.78 | P2RX7 (0.38) | NPC1P2RX7TGFBR1CES1GRM5 | |
| SCHEMBL23389992 | 0.78 | P2RX7 (0.38) | NPC1P2RX7TGFBR1CES1GRM5 | |
| SCHEMBL2237588 | 0.78 | P2RX7 (0.62) | NPC1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14576794 | 0.75 | NPC1 (0.48) | NPC1MEN1KMT2ARAB9AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407958-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2008-08-05 | — | — | US | disclosed |
| EP-1620426-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | In2gen Co., Ltd. (KR) | 2006-02-01 | — | — | EP | disclosed |
| US-20050261299-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2005-11-24 | — | — | US | disclosed |
| WO-2005103028-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | IN2GEN CO., LTD (KR) | 2005-11-03 | — | — | WO | disclosed |
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002055077-A1 | USE OF IMIDAZOLYL CYCLIC ACETAL DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES MEDIATED BY THE ALK5 RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261299-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ACVR1, ACVRL1, ACVR1B | NPC1 3585/4885MEN1 873/4885KMT2A 1460/4885 |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | NPC1 1981/4885MEN1 3492/4885KMT2A 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.